# 3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

> **NCT00064051** · PHASE2 · COMPLETED · sponsor: **Vion Pharmaceuticals**

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** gemcitabine hydrochloride
- **DRUG:** triapine

## Key facts

- **NCT ID:** NCT00064051
- **Lead sponsor:** Vion Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-01
- **Primary completion:** 2006-08
- **Final completion:** 2008-08
- **Target enrollment:** — (—)
- **Last updated:** 2013-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00064051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00064051, "3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00064051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*